Dr. Noam Emanuel, Co-Founder and CSO of PolyPid, a late-stage biopharma company aiming to improve surgical outcomes, discusses the second most prevalent type of Healthcare-Associated Infection (HAI), Surgical Site Infections (SSIs) which are responsible for 20 percent of all HAIs in US hospitals and often result in readmission and extended hospital stays. Current SSI prevention lies in IV antibiotic administration, but its systemic administration has limited efficacy and can result in resistance and toxicity. PolyPid is working to tackle this issue with its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology that pairs with medications, to enable precise delivery of drugs at effective release rates over durations ranging from several days to months.
Dr. Emanuel has vast experience in biotechnology projects, including development of drug delivery systems and immunology. His extensive expertise includes immunotherapy, vaccines, immunodiagnostics, systemic and local drug-delivery, and medical devices. Dr. Emanuel has a number of approved patents in the field of drug delivery and diagnostics. Dr. Emanuel is a co-founder of PolyPid and served as its CEO during the company’s first three years. He received his Ph.D. degree from the Faculty of Medicine at the Hebrew University of Jerusalem.